Отправляет email-рассылки с помощью сервиса Sendsay

Пресс-релизы. Медицина и фармацевтика

Рассылка закрыта

При закрытии подписчики были переданы в рассылку "Subscribe. Здоровье" на которую и рекомендуем вам подписаться.

Вы можете найти рассылки сходной тематики в Каталоге рассылок.

←   Июнь 2004   →
 1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
16.06.2004
17:30:21
19:02:42
17
18
19
20
21
22
22.06.2004
14:42:32
16:34:30
23
24
25
26
27
28
29
30
Автор
Subscribe.Ru

Статистика

873 подписчиков
+1 за неделю
←   Все выпуски   →

Пресс-релизы. Медицина и фармацевтика SANOFI-SYNTHELABO’S OFFER FOR AVENTIS. EXPIRATION DATE OF OFFERS


Информационный Канал Subscribe.Ru 
Заголовок: SANOFI-SYNTHELABO’S OFFER FOR AVENTIS. EXPIRATION DATE OF OFFERS

Компания: PR-agency "Creative-Studio PRESSTO"

Paris, France - June 1, 2004 - On June 1, 2004, the Autoritй des marchйs financiers
(AMF) — the French stock market regulator — announced that it had set June 30,
2004 as the expiration date of Sanofi-Synthelabo’s (PARIS: SAN, NYSE: SNY) revised
offer for the ordinary shares of Aventis (PARIS: AVE, FRANKFURT: AVE.ETR, NYSE:
AVE).
Accordingly, Sanofi-Synthelabo confirms that the French offer and the German
offer will expire at 23:00 hr (Central European Summer Time), and the U.S. offer
will expire simultaneously at 5:00 p.m. (Eastern Daylight Time), on Wednesday,
June 30, 2004.
Sanofi-Synthelabo confirms that holders of Aventis securities may tender, or
withdraw their tendered, Aventis securities at any time until the expiration
of the offers.  

In accordance with article 7 of the COB rule no. 2002-04, this press release
was transmitted to the Autoritй des marchйs financiers (AMF) before its publication.

Important Information:  In connection with the proposed acquisition of Aventis,
Sanofi-Synthйlabo has filed a registration statement on Form F-4 (File no. 333-112314),
including a prospectus and a prospectus supplement relating to the revised offer,
and will file additional documents with the SEC.  Investors are urged to read
the registration statement, including the prospectus and the prospectus supplement
relating to the revised offer, and any other relevant documents filed with the
SEC, including all amendments and supplements, because they contain important
information.  Free copies of the registration statement, as well as other relevant
documents filed with the SEC, may be obtained at the SEC’s web site at www.sec.gov.
 The prospectus and the prospectus supplement relating to the revised offer and
other transaction-related documents are being mailed to Aventis security holders
eligible to participate in the U.S. offer and additional copies may be obtained
for free from!
 MacKenzie Partners, Inc., the information agent for the U.S. offer, at the following
address: 105, Madison Avenue, New York, New York 10016; telephone: 1-(212) 929-5500
(call collect) or 1-(800) 322-2885 (toll-free call); e-mail proxy@mackenziepartners.com.
In France, holders of Aventis securities are requested, with respect to the offer,
to refer to the prospectus supplement (note d’information complйmentaire), which
has been granted visa number 04-384 by the Autoritй des marchйs financiers ("AMF")
and which is available on the website of the AMF (www.amf-france.org) and without
cost from: BNP Paribas Securities Services, GIS-Emetteurs, Service Logistique,
Les Collines de l’Arche, 75450 Paris Cedex 9 and to the recommendation statement
(note d’information en rйponse) which has been granted visa number 04-510.
The public offer to holders of Aventis ordinary shares located in Germany (the
"German Offer") is being made in accordance with applicable German law and pursuant
to an offer document/sales prospectus, which is available free of charge at BNP
Paribas Securities Services, Grьneburgweg 14, D-60322 Frankfurt am Main (Fax:
069 - 152 05 277) and on the website of the Company (www.sanofi-synthelabo.com).
 Any decision to tender Aventis ordinary shares in exchange for Sanofi-Synthйlabo
ordinary shares under the German Offer must be taken exclusively with regard
to the terms and conditions of the German Offer, as well as with regard to the
information included in the offer document/sales prospectus, including any amendments
thereto, issued in Germany.
The French Offer, the U.S. Offer and the German Offer are being made on substantially
the same terms and completion of these offers is subject to the same conditions.
 It is intended that the three offers will expire at the same time. 
Investors and security holders may obtain a free copy of the Form 20-F filed
with the SEC on April 2, 2004 and any other documents filed by Sanofi-Synthйlabo
with the SEC at www.sec.gov as well as of the Reference Document filed with the
AMF on April 2, 2004 (N° 04-0391) at www.amf-france.org or directly from Sanofi-Synthйlabo
on our web site at: www.sanofi-synthelabo.com.

Контактная информация:
------------------------------
Контактное лицо:   Elena Kulkova
project manager
E-mail:         y.kulkova@pressto.ru
Телефон:        +7 095 101-35-23

http://subscribe.ru/
E-mail: ask@subscribe.ru 		Отписаться
Убрать рекламу

В избранное